# OnCo record ca184-043-ipilimumab (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/ca184-043-ipilimumab/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "ca184-043-ipilimumab", "NCT00861614" ;
  schema:name "CA184-043"@en ;
  schema:alternateName "CA184-043"@en, "ipilimumab after radiotherapy in mCRPC"@en ;
  schema:description "The first big immunotherapy trial in prostate cancer. It missed by a hair, and the way it missed, harm early and benefit late, was the clue nobody managed to cash in."@en ;
  schema:url <https://onco.cc/trials/ca184-043-ipilimumab/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT00861614>, <https://doi.org/10.1016/S1470-2045(14)70189-5> ;
  onco:status "negative" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mcrpc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/ctla4/> ;
  onco:drugs <https://onco.cc/drugs/ipilimumab/> ;
  onco:companies <https://onco.cc/companies/bms/> ;
  onco:terms <https://onco.cc/terms/castration-resistance/>, <https://onco.cc/terms/bone-metastases/> ;
  onco:trials <https://onco.cc/trials/imbassador250/>, <https://onco.cc/trials/impact-sipuleucel-t/>, <https://onco.cc/trials/keynote-921/> .